New Delhi: GlaxoSmithKline Pharmaceuticals Ltd has suspended the distribution and supply of ranitidine hydrochloride products to all markets, including India, as a precautionary measure after regulatory authorities detected a carcinogen N-nitrosodimethylamine in its products. Based on the information received and correspondence with regulatory authorities, GSK made the decision to suspend the release, distribution and supply of all dose forms of …
